Literature DB >> 24621844

Total serum bilirubin as a negative prognostic factor in idiopathic canine chronic hepatitis.

Aida Gómez Selgas1, Nicholas Bexfield, Timothy J Scase, Mark A Holmes, Penny Watson.   

Abstract

Total serum bilirubin (TBIL) is used as a prognostic factor in chronic hepatitis (CH) in human beings. To date, the authors are unaware of any studies looking at the value of TBIL as a prognostic factor in idiopathic canine CH. The objective of the current study was to assess if TBIL is a negative prognostic factor in idiopathic canine CH, and to identify other prognostic factors. Thirty-nine dogs with histologically confirmed idiopathic CH admitted to 2 referral centers between 1999 and 2010 were included in the study. Patients with concurrent diseases that could affect TBIL or the survival time were excluded. Total serum bilirubin was measured prior to liver biopsy, and CH was diagnosed according to standardized histological criteria. Survival time was calculated from time of diagnosis to time of death or euthanasia. Cox proportional hazard analysis was performed to identify prognostic factors. The mean survival time for the 39 dogs included in the analysis was 197 days (1-2,677), and the mean total serum bilirubin was 11 μmol/l (2-265). Total serum bilirubin was statistically significantly associated with survival (odds ratio = 1.082, P = 0.047) as were weight (odds ratio = 1.028, P = 0.028) and the presence of ascites (odds ratio = 6.758, P = 0.013). The current study demonstrates that TBIL could be used as an additional prognostic factor in canine CH.

Entities:  

Keywords:  Bilirubin; dogs; liver disease; prognosis; survival

Mesh:

Substances:

Year:  2014        PMID: 24621844     DOI: 10.1177/1040638713520602

Source DB:  PubMed          Journal:  J Vet Diagn Invest        ISSN: 1040-6387            Impact factor:   1.279


  8 in total

1.  Thromboelastography in Dogs with Chronic Hepatopathies.

Authors:  W Fry; C Lester; N M Etedali; S Shaw; A DeLaforcade; C R L Webster
Journal:  J Vet Intern Med       Date:  2017-01-18       Impact factor: 3.333

2.  Hepatocyte expression and prognostic importance of senescence marker p21 in liver histopathology samples from dogs with chronic hepatitis.

Authors:  Andre J Kortum; Emilie A Cloup; Tim L Williams; Fernendo Constantino-Casas; Penny J Watson
Journal:  J Vet Intern Med       Date:  2018-08-22       Impact factor: 3.333

3.  Retrospective evaluation of cyclosporine in the treatment of presumed idiopathic chronic hepatitis in dogs.

Authors:  Tarini Ullal; Yoko Ambrosini; Sangeeta Rao; Cynthia R L Webster; David Twedt
Journal:  J Vet Intern Med       Date:  2019-08-08       Impact factor: 3.333

4.  ACVIM consensus statement on the diagnosis and treatment of chronic hepatitis in dogs.

Authors:  Cynthia R L Webster; Sharon A Center; John M Cullen; Dominique G Penninck; Keith P Richter; David C Twedt; Penny J Watson
Journal:  J Vet Intern Med       Date:  2019-03-07       Impact factor: 3.333

5.  Effect of dilution of canine blood samples on the specificity of saline agglutination tests for immune-mediated hemolysis.

Authors:  Prudence L Sun; Unity Jeffery
Journal:  J Vet Intern Med       Date:  2020-11-10       Impact factor: 3.333

6.  Clinical findings and assessment of factors associated with survival in dogs presenting with hyperbilirubinaemia: 115 cases in Victoria, Australia (2015-2020).

Authors:  Abigail Brough; Charles Caraguel; Susan Ciaravolo; Alison Stickney
Journal:  Vet Rec Open       Date:  2022-08-16

7.  Presence of Systemic Inflammatory Response Syndrome Predicts a Poor Clinical Outcome in Dogs with a Primary Hepatitis.

Authors:  Scott Kilpatrick; Margaret Dreistadt; Polly Frowde; Roger Powell; Elspeth Milne; Sionagh Smith; Linda Morrison; Adam G Gow; Ian Handel; Richard J Mellanby
Journal:  PLoS One       Date:  2016-01-25       Impact factor: 3.240

8.  Protective effects of Chinese Fenggang zinc selenium tea on metabolic syndrome in high-sucrose-high-fat diet-induced obese rats.

Authors:  Jie Yu; Jing Yang; Mizhuan Li; Xuesong Yang; Pan Wang; Jie Xu
Journal:  Sci Rep       Date:  2018-02-23       Impact factor: 4.379

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.